Fig. 2.

Puromycin (puro) labeling under hypertrophic growth. A: hypertrophic growth in neonatal rat ventricular myocytes (NRVMs). Puromycin was introduced to monitor cell growth, which did not affect the induction of β-myosin heavy chain (β-MHC) or regulator of calcineurin 1.4 (Rcan1.4), two markers of hypertrophic growth. B: immunofluorescence staining showed incorporation of puromycin after phenylephrine (PE) treatment in NRVMs. WB, Western blot analysis; veh, vehicle; DAPI, 4′,6′-diamidino-2-phenylindole. Original scale bars = 100 μm.